Eli Lilly's Experimental GLP-1 Pill Shows Promising Weight Loss Results
Eli Lilly's experimental GLP-1 pill, orforglipron, demonstrated significant weight loss in a study of over 3,000 adults, with plans for regulatory submission by year-end.
Subscribe to unlock this story
We really don't like cutting you off, but you've reached your monthly limit. At just $5/month, subscriptions are how we keep this project going. Start your free 7-day trial today!
Get StartedHave an account? Sign in
Overview
- Eli Lilly's experimental GLP-1 pill, orforglipron, showed promising weight loss in a study involving over 3,000 adults with obesity or overweight conditions.
- Participants on the highest dose lost at least 10% of their body weight, with those taking it daily for nearly 1.5 years averaging 12% or 27 pounds weight loss.
- While effective, the pill caused gastrointestinal side effects like nausea and diarrhea, but was generally deemed safe for individuals with obesity.
- Eli Lilly intends to submit orforglipron for regulatory review and potential FDA approval by the end of the current year.
- The potential approval of orforglipron could significantly expand global access to GLP-1 medications, offering a new treatment option for obesity.
Report issue
Read both sides in 5 minutes each day
Analysis
Analysis unavailable for this viewpoint.
Articles (3)
Center (0)
No articles found in the Center category
FAQ
Orforglipron is an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly that helps reduce weight by mimicking the GLP-1 hormone, which regulates appetite and food intake, leading to clinically meaningful weight loss in adults with obesity or overweight.
In the phase 3 ATTAIN-1 trial involving over 3,000 adults, orforglipron taken daily led to an average weight loss of 12.4% (about 27.3 pounds) at 72 weeks, with all doses meeting primary and key secondary efficacy endpoints compared to placebo, and showing a safety profile consistent with existing injectable GLP-1 therapies.
The main side effects reported were gastrointestinal issues such as nausea and diarrhea, but overall the medication was generally considered safe for use in individuals with obesity, with no liver safety signals observed and lower treatment discontinuation rates compared to placebo.
Orforglipron showed slightly less weight loss in late-stage trials (around 11-12%) compared to injectable GLP-1 treatments like Novo Nordisk's Wegovy, which demonstrate approximately 15-21% weight loss; however, orforglipron offers the convenience of oral administration.
Eli Lilly plans to submit orforglipron for regulatory review and potential FDA approval by the end of 2025, with expectations to expand global access to GLP-1 medications for obesity treatment.
History
- This story does not have any previous versions.